Summary

for females ages 18 years and up (full criteria)
at Orange, California and other locations
study started
estimated completion
Krishnansu Tewari, MD

Description

Summary

This is an open label, multi-center trial of tisotumab vedotin in combination with bevacizumab, pembrolizumab, or carboplatin in subjects with recurrent or stage IVB cervical cancer. The trial consists of two-parts a dose escalation part and an expansion part. The expansion part of the trial will be initiated once the Recommended Phase 2 Dose (RP2D) of the combinations have been determined in the dose escalation part.

Official Title

A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer

Details

The dose escalation part will occur in cervical cancer subjects who have progressed during or after standard of care therapy and who are intolerant or ineligible to receive standard of care treatments. Arm A will be conducted by escalating doses of both tisotumab vedotin and bevacizumab. Dose escalations of the tisotumab vedotin + pembrolizumab and tisotumab vedotin + carboplatin combinations (Arms B and C, respectively) will be conducted by combining fixed doses of either pembrolizumab or carboplatin with increasing doses of tisotumab vedotin.

The dose expansion part will consist of subjects with recurrent or stage IVB cervical cancer, who have not received prior systemic therapy for their recurrent or stage IVB disease, Arms D and E being treated with tisotumab vedotin + carboplatin or tisotumab vedotin + pembrolizumab, respectively, or subjects, who have progressed on or after standard of care treatments, Arm F treated with tisotumab vedotin + pembrolizumab. Subjects enrolled to these arms will receive the RP2D of tisotumab vedotin established in the dose escalation part.

Keywords

Cervical Cancer cervical carcinoma Uterine Cervical Neoplasms Bevacizumab Pembrolizumab Carboplatin Tisotumab Vedotin A: Tisotumab Vedotin + bevacizumab B: Tisotumab vedotin + pembrolizumab C: Tisotumab vedotin + carboplatin D: Tisotumab vedotin + carboplatin E: Tisotumab vedotin + pembrolizumab F: Tisotumab vedotin + pembrolizumab

Eligibility

You can join if…

Open to females ages 18 years and up

  • Must have squamous, adenosquamous, or adenocarcinoma of the cervix and progressed on or after standard of care treatments or are ineligible or intolerant to standard of care for recurrent or stage IVB cervical cancer (Arms A, B and C only).
  • Must have squamous, adenosquamous, or adenocarcinoma of the cervix and must not have received prior systemic therapy for recurrent or stage IVB cervical cancer (Arms D and E only).
  • Must have squamous, adenosquamous, or adenocarcinoma of the cervix and progressed on or after at least one but no more than two standard of care treatments for recurrent or stage IVB cervical cancer (Arm F only).
  • Must have baseline measurable disease per RECIST v1.1.
  • Must be at least 18 years of age on the day of signing informed consent (All Arms).
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (All Arms).
  • Is not pregnant, breastfeeding, or expecting to conceive children within the projected duration of the trial and for at least 6 months after the last trial treatment administration
  • Women of childbearing potential must agree to use adequate contraception during and for 6 months after the last dose of trial treatment administration.
  • Must sign an informed consent form (ICF) indicating the trial subject understands the purpose of and procedures required for the trial and are willing to participate in the trial (All Arms).

You CAN'T join if...

  • Has clinically relevant bilateral hydronephrosis which cannot be alleviated by ureteral stents or percutaneous drainage. (All Arms)
  • Has clinical signs or symptoms of gastrointestinal obstruction and requires parenteral hydration and/or nutrition. Post-operative obstructions within 4 weeks of abdominal surgery are permitted. (All Arms)
  • Has clinically significant bleeding issues or risks
  • Prior history (within 3 months) or current evidence of hemoptysis (1/2 teaspoon or more) (Arm A only)
  • Recent (within 4 weeks of first dose of trial treatment) clinically significant gastrointestinal or vaginal bleeding requiring PRBC transfusion (Arm A only)
  • Recent (within 4 weeks of first dose of trial treatment) evidence of wound healing complications that require medical intervention (Arm A only)
  • Has active ocular surface disease at baseline. Subjects with prior history of cicatricial conjunctivitis are ineligible (All Arms).
  • Clinically significant cardiac disease
  • Requires anti-coagulation therapy

Locations

  • Univ California, Irvine Medical Center accepting new patients
    Orange California 92868 United States
  • Montana Cancer Consortium accepting new patients
    Billings Montana 59102 United States

Lead Scientist

  • Krishnansu Tewari, MD
    Professor, Obstetrics and Gynecology. Authored (or co-authored) 167 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Genmab
ID
NCT03786081
Phase
Phase 1/2
Study Type
Interventional
Last Updated